APLLTD Stock Overview
Develops, manufactures, and markets pharmaceutical products in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Alembic Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,080.40 |
| 52 Week High | ₹1,119.00 |
| 52 Week Low | ₹682.30 |
| Beta | 0.68 |
| 11 Month Change | 27.81% |
| 3 Month Change | 15.14% |
| 1 Year Change | 56.41% |
| 33 Year Change | 14.21% |
| 5 Year Change | 101.72% |
| Change since IPO | 2,162.62% |
Recent News & Updates
Recent updates
Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt
May 05Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jan 17Are Alembic Pharmaceuticals Limited (NSE:APLLTD) Investors Paying Above The Intrinsic Value?
Dec 17Shareholder Returns
| APLLTD | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 9.5% | -0.8% | -1.3% |
| 1Y | 56.4% | 46.4% | 43.0% |
Return vs Industry: APLLTD exceeded the Indian Pharmaceuticals industry which returned 46.3% over the past year.
Return vs Market: APLLTD exceeded the Indian Market which returned 43% over the past year.
Price Volatility
| APLLTD volatility | |
|---|---|
| APLLTD Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.6% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: APLLTD has not had significant price volatility in the past 3 months.
Volatility Over Time: APLLTD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1907 | 14,858 | Chirayu Amin | alembicpharmaceuticals.com |
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products.
Alembic Pharmaceuticals Limited Fundamentals Summary
| APLLTD fundamental statistics | |
|---|---|
| Market cap | ₹212.37b |
| Earnings (TTM) | ₹6.16b |
| Revenue (TTM) | ₹62.29b |
34.5x
P/E Ratio3.4x
P/S RatioIs APLLTD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLLTD income statement (TTM) | |
|---|---|
| Revenue | ₹62.29b |
| Cost of Revenue | ₹17.96b |
| Gross Profit | ₹44.32b |
| Other Expenses | ₹38.17b |
| Earnings | ₹6.16b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 31.33 |
| Gross Margin | 71.16% |
| Net Profit Margin | 9.89% |
| Debt/Equity Ratio | 8.9% |
How did APLLTD perform over the long term?
See historical performance and comparison